AstraZeneca in Orchid tie-in

 

AstraZeneca is to collaborate in genetic research with America's Orchid BioSciences in an effort to personalise drugs.

Separately, Orchid agreed to buy AstraZeneca's Cellmark Diagnostics, a genetic testing unit, for an undisclosed sum. AstraZeneca shares rose 34p to 3075p.